Kaplan–Meier and log‐rank analysis comparing (A) fr

Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy. Jacobs C, Tumati V, Kapur P, Yan J, Xie XJ, Hannan R, Hsieh JT, Kim DW, Saha D - Cancer Med (2015) Bottom Line: We hypothesized that pretreatment DAB2IP reduction would predict worse prostate cancer-specific survival (PCSS).Twenty-eight percent (22/79) of pretreatment biopsies revealed DAB2IP-reduction.Patients with reduced DAB2IP demonstrated worse outcome compared to patients retaining DAB2IP, including FFBF (4-year: 34 vs. 92%; P < 0.0001), CRFS (4-year: 58 vs. 96%; P = 0.0039), DMFS (4-year: 58 vs. 100%; P = 0.0006), and PCSS (5-year: 83 vs. 100%; P = 0.0102). View Article: PubMed Central - PubMed Affiliation: Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, 75390. No MeSH data available. Related in: MedlinePlus	© Copyright Policy - creativeCommonsBy Related In: Results - Collection License Show All Figures getmorefigures.php?uid=PMC4940806&req=5 cam4554-fig-0001: Kaplan–Meier and log‐rank analysis comparing (A) freedom from biochemical failure, (B) castration resistance‐free survival, (C) distant metastasis‐free survival, (D) prostate cancer‐specific survival, and (E) overall survival based on pretreatment tumor DAB2IP status. Mentions: Pretreatment tumor reduction in DAB2IP as evidenced by prostate biopsy samples correlated strongly with worse outcome in every endpoint measured except death from any cause (see Table 2). Reduced DAB2IP portended a significantly worse FFBF (P < 0.0001), CRFS (P = 0.0039), DMFS (P = 0.0006), and PCSS (P = 0.0102). Kaplan–Meier estimates of these four significant endpoints can be seen in Figure 1. By 4‐years postradiotherapy, the biochemical failure rate was a staggering 66% in the DAB2IP‐reduced group compared to only 8% in the DAB2IP‐retained group at that point. By 5‐years postradiotherapy, the prostate cancer‐specific mortality rate was 17% in the DAB2IP‐reduced group whereas no one in the DAB2IP‐retained group had died due to their malignancy.

Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy.

Jacobs C, Tumati V, Kapur P, Yan J, Xie XJ, Hannan R, Hsieh JT, Kim DW, Saha D - Cancer Med (2015)

Bottom Line: We hypothesized that pretreatment DAB2IP reduction would predict worse prostate cancer-specific survival (PCSS).Twenty-eight percent (22/79) of pretreatment biopsies revealed DAB2IP-reduction.Patients with reduced DAB2IP demonstrated worse outcome compared to patients retaining DAB2IP, including FFBF (4-year: 34 vs. 92%; P < 0.0001), CRFS (4-year: 58 vs. 96%; P = 0.0039), DMFS (4-year: 58 vs. 100%; P = 0.0006), and PCSS (5-year: 83 vs. 100%; P = 0.0102).

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, 75390.

No MeSH data available.

Related in: MedlinePlus

Kaplan–Meier and log‐rank analysis comparing (A) freedom from biochemical failure, (B) castration resistance‐free survival, (C) distant metastasis‐free survival, (D) prostate cancer‐specific survival, and (E) overall survival based on pretreatment tumor DAB2IP status.

Related In: Results - Collection

License

Show All Figures

getmorefigures.php?uid=PMC4940806&req=5

cam4554-fig-0001: Kaplan–Meier and log‐rank analysis comparing (A) freedom from biochemical failure, (B) castration resistance‐free survival, (C) distant metastasis‐free survival, (D) prostate cancer‐specific survival, and (E) overall survival based on pretreatment tumor DAB2IP status.

Mentions: Pretreatment tumor reduction in DAB2IP as evidenced by prostate biopsy samples correlated strongly with worse outcome in every endpoint measured except death from any cause (see Table 2). Reduced DAB2IP portended a significantly worse FFBF (P < 0.0001), CRFS (P = 0.0039), DMFS (P = 0.0006), and PCSS (P = 0.0102). Kaplan–Meier estimates of these four significant endpoints can be seen in Figure 1. By 4‐years postradiotherapy, the biochemical failure rate was a staggering 66% in the DAB2IP‐reduced group compared to only 8% in the DAB2IP‐retained group at that point. By 5‐years postradiotherapy, the prostate cancer‐specific mortality rate was 17% in the DAB2IP‐reduced group whereas no one in the DAB2IP‐retained group had died due to their malignancy.